30093-97-1

Basic information

• Product Name: 4,5-dihydro-3,4,4-trimethyloxazolium iodide
• Synonyms: 4,5-dihydro-3,4,4-trimethyloxazolium iodide;Einecs 250-044-1
• CAS NO: 30093-97-1
• Molecular Formula: C₆H₁₂NO*I
• Molecular Weight: 241.07005
• EINECS: 250-044-1
• Mol File: 30093-97-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,5-dihydro-3,4,4-trimethyloxazolium iodide(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-dihydro-3,4,4-trimethyloxazolium iodide(30093-97-1)
• EPA Substance Registry System: 4,5-dihydro-3,4,4-trimethyloxazolium iodide(30093-97-1)

Safety Data

• Hazardous Substances Data: 30093-97-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C6H12NO.HI/c1-6(2)4-8-5-7(6)3;/h5H,4H2,1-3H3;1H/q+1;/p-1

Upstream product

• 30093-99-3 4,4-dimethyl-2-oxazoline 
• 74-88-4 methyl iodide 
• 504-77-8 4,5-dihydro-1,3-oxazol 

Downstream Products

• 3179-31-5 1H-[1,2,4]triazole-3-thiol 
• 3179-31-5 3-mercapto-1,2,4-triazole 
• 491-36-1 4-Hydroxyquinazoline 
• 51-17-2 benzoimidazole 
• 2843-27-8 N-(2-hydroxyphenyl)formamide 
• 95-16-9 1,3-Benzothiazole 
• 182363-00-4 (Z)-3-[(2-Hydroxy-1,1-dimethyl-ethyl)-methyl-amino]-1-phenyl-propenone 
• 184955-24-6 1-Phenyl-2-(3,4,4-trimethyl-oxazolidin-2-yl)-ethanone 

Relevant articles and documents

Pictet-Spengler reaction: Is carbonyl the best choice? A highly diastereoselective alternative approach to trans-1,3-disubstituted tetrahydro-β-carbolines

Unprecedented 1,2,3-trisubstituted tetrahydro-β-carbolines (THBCs) have been synthesized via a short and highly diastereoselective synthetic route. The key step of the sequence is a flexible variant of the Pictet-Spengler reaction employing synthetic equivalents of several non-available carbonyl compounds. Using one such synthon, the resultant THBC could be further ring- closed to a tetracyclic indole alkaloidal skeleton. (C) 2000 Elsevier Science Ltd.

LEUKOTRIENE ANTAGONISTS

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, processes for the preparation thereof, and pharmaceutical compositions containing such compounds.This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

Leukotriene antagonist thiadiazoles have been prepared.

ESTER PRODRUGS

This invention relates to ester prodrugs for alkanoic acid compounds useful as leukotriene antagonists, and pharmaceutical compositions containing such ester prodrug compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and heteroarylthio substituents which are useful as leukotriene antagonists, pharmaceutical compositions containing such compounds, and methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to methods of treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

A method for inhibiting the effects of LTB4 comprises administration of an effective amount of a compound represented by the following structural formula (I) STR1 wherein m is 1 or 2; n is 1, 2 or 3; p is 0, 1, or 2; R' is hydrogen or methyl; R is phenyl substituted with A, R1 and R2 wherein R1 and R2 are independently selected from either (1) (S)a --(CH2)b --(T)c --B wherein a is 0 or 1; b is 5 to 12; c is 0 or 1; S and T are independently sulfur, oxygen, or CH2 with the proviso that S or T are not sulfur when p is 1 or 2; and B is C1-4 alkyl, ethynyl, trifluoromethyl, or phenyl optionally monosubstituted with Br, Cl, CF3, C1-4 alkoxy, C1-4 alkyl, methylthio, or trifluoromethylthio; or (2) hydrogen bromo, chloro, methyl, trifluoromethyl, methoxy or nitro; and A is selected from (2) as defined above or a pharmaceutically acceptable salt thereof. Such methods are useful in the treatment of diseases in which LTB4 is a factor.

THIOPHENYL ALKANOIC ACIDS USEFUL AS LEUKOTRIENE ANTAGONISTS

This invention relates to alkanoic acid compounds having phenyl and thio substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. This invention also relates to treating diseases in which leukotrienes are a factor by administration of an effective amount of the above compounds or compositions.

Leukotriene antagonists

This invention relates to alkanoic acid compounds having phenyl and sulfinyl or sulfonyl substituents which are useful as leukotriene antagonists and pharmaceutical compositions containing such compounds. The invention also relates to the use of such compound for treatment of diseases in which leukotrienes are a factor.